In a Jittery Market, a Glut of Art Fairs Is Again Putting Galleries Through the Wringer—With No End in Sight
Remember when a crammed calendar of global art fairs drove art dealers to desperation? Well, it's ba-aack.
Source: artnet.com
Page 8 - Simon Fox News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Simon Fox. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Simon Fox Today - Breaking & Trending Today
Positive Topline Results for Antihypertensive Zilebesiran
The investigational siRNA therapeutic showed consistent and sustained reductions in systolic blood pressure in a phase 2 study of adults with hypertension.
Source: medscape.com
![[Herald Interview] Frieze CEO sees permeating local cultural scene as key to fair's success - Vimarsana News](https://res.heraldm.com/content/image/2023/09/07/20230907000632_0.jpg?1)
[Herald Interview] Frieze CEO sees permeating local cultural scene as key to fair's success
As the date for the second edition of Frieze Seoul approached, museums and galleries in Seoul unveiled their plans to ensure the fair becomes the highlight of the year. At the same time, galleries and global auctioneers are exploring opportunities to establish permanent spaces within the city. “I was absolutely overwhelmed by the enthusiasm that everybody in Seoul has for Frieze Seoul, and of course for Kiaf Se...
Source: koreaherald.com
Frieze Seoul returns with more collectors from Asia
Following a splashy debut last year, Frieze Seoul returned to COEX in the ritzy Gangnam District in the southern part of the capital this week to offer another two-for-one art fair experience with its local counterpart Kiaf Seoul.
Source: koreatimes.co.kr
Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk
- Zilebesiran Met Primary Endpoint Demonstrating Greater than 15 mmHg Reduction of Systolic Blood Pressure at Three Months of Treatment Compared to Placebo at Two Highest Single Doses Evaluated - -...
Source: marketscreener.com